A long­time Pfiz­er chief's ul­tra-qui­et biotech re-emerges with new cash and plans for the clin­ic

In Au­gust 2018, a tiny biotech spin­out from Cor­nell an­nounced they had hired for­mer high-rank­ing Pfiz­er ex­ec­u­tive Geno Ger­mano as CEO. And then they said noth­ing else. For two years. Lit­er­al­ly, the com­pa­ny, called Elu­ci­da On­col­o­gy, did not is­sue a sin­gle oth­er press re­lease un­til this past Oc­to­ber, when they hired a chief med­ical of­fi­cer.

Now, though, Elu­ci­da seems to be ready to start tak­ing the lid off their op­er­a­tions. On Tues­day at JP Mor­gan, Ger­mano walked in­vestors through the nanopar­ti­cle tech­nol­o­gy they’ve been de­vel­op­ing for can­cer. And the same day, the com­pa­ny an­nounced a new fi­nanc­ing, rais­ing $44 mil­lion in a Se­ries “A-1” round meant to pro­pel them in­to the clin­ic this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.